Barclays’s G1 Therapeutics, Inc. Common Stock GTHX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
-23,032
| Closed | -$52.5K | – | 5542 |
|
|
2024
Q2 | $52.5K | Buy |
23,032
+16,730
| +265% | +$63.9K | ﹤0.01% | 4190 |
|
|
2024
Q1 | $27.2K | Hold |
6,302
| – | – | ﹤0.01% | 4719 |
|
|
2023
Q4 | $19.2K | Hold |
6,302
| – | – | ﹤0.01% | 4909 |
|
|
2023
Q3 | $9.07K | Hold |
6,302
| – | – | ﹤0.01% | 4317 |
|
|
2023
Q2 | $15.7K | Sell |
6,302
-2,463
| -28% | -$6.73K | ﹤0.01% | 4171 |
|
|
2023
Q1 | $23.5K | Sell |
8,765
-17,710
| -67% | -$85.1K | ﹤0.01% | 4625 |
|
|
2022
Q4 | $144K | Sell |
26,475
-87,156
| -77% | -$730K | ﹤0.01% | 4021 |
|
|
2022
Q3 | $1.42M | Buy |
+113,631
| New | +$1.3M | ﹤0.01% | 1975 |
|
|
2022
Q2 | – | Sell |
-224
| Closed | -$2K | – | 5331 |
|
|
2022
Q1 | $2K | Sell |
224
-65,289
| -100% | -$619K | ﹤0.01% | 4801 |
|
|
2021
Q4 | $669K | Buy |
65,513
+48,788
| +292% | +$622K | ﹤0.01% | 3056 |
|
|
2021
Q3 | $224K | Buy |
16,725
+16,628
| +17,142% | +$271K | ﹤0.01% | 3558 |
|
|
2021
Q2 | $2K | Sell |
97
-237
| -71% | -$5.26K | ﹤0.01% | 4811 |
|
|
2021
Q1 | $8K | Sell |
334
-91,818
| -100% | -$2.13M | ﹤0.01% | 4461 |
|
|
2020
Q4 | $1.66M | Buy |
92,152
+72,854
| +378% | +$1.09M | ﹤0.01% | 2393 |
|
|
2020
Q3 | $222K | Sell |
19,298
-4,606
| -19% | -$76K | ﹤0.01% | 3782 |
|
|
2020
Q2 | $579K | Buy |
23,904
+19,142
| +402% | +$317K | ﹤0.01% | 3229 |
|
|
2020
Q1 | $52K | Sell |
4,762
-38,110
| -89% | -$712K | ﹤0.01% | 5213 |
|
|
2019
Q4 | $1.13M | Buy |
42,872
+37,531
| +703% | +$878K | ﹤0.01% | 3560 |
|
|
2019
Q3 | $122K | Sell |
5,341
-20,382
| -79% | -$642K | ﹤0.01% | 5332 |
|
|
2019
Q2 | $789K | Buy |
25,723
+19,602
| +320% | +$413K | ﹤0.01% | 3929 |
|
|
2019
Q1 | $101K | Buy |
6,121
+3,266
| +114% | +$62K | ﹤0.01% | 5354 |
|
|
2018
Q4 | $55K | Sell |
2,855
-17,515
| -86% | -$656K | ﹤0.01% | 5424 |
|
|
2018
Q3 | $1.06M | Buy |
20,370
+16,703
| +455% | +$911K | ﹤0.01% | 3556 |
|
|
2018
Q2 | $159K | Buy |
3,667
+319
| +10% | +$13.7K | ﹤0.01% | 4917 |
|
|
2018
Q1 | $124K | Sell |
3,348
-729
| -18% | -$19.5K | ﹤0.01% | 5228 |
|
|
2017
Q4 | $81K | Sell |
4,077
-642
| -14% | -$13.8K | ﹤0.01% | 5408 |
|
|
2017
Q3 | $118K | Buy |
4,719
+3,919
| +490% | +$72.4K | ﹤0.01% | 4815 |
|
|
2017
Q2 | $14K | Buy |
+800
| New | +$14K | ﹤0.01% | 5942 |
|
Barclays's GTHX Position: Q3 2024 in Review
Barclays sold out of G1 Therapeutics, Inc. Common Stock (GTHX) in Q3 2024, closing a stake of 23,032 shares — an estimated $52.5K sold.
Barclays first reported a position in GTHX in Q2 2017 and held it in 28 quarters. The position peaked at $1.66M in Q4 2020. 0 funds tracked by Wall St. Rank hold GTHX as of Q3 2024.
- Barclays reported no remaining G1 Therapeutics, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
- Barclays sold 23,032 G1 Therapeutics, Inc. Common Stock shares in Q3 2024, an estimated $52.5K.
- Barclays first reported a position in G1 Therapeutics, Inc. Common Stock in Q2 2017 and held it in 28 quarters.
- Barclays's G1 Therapeutics, Inc. Common Stock position peaked at $1.66M in Q4 2020.
- 0 funds tracked by Wall St. Rank held G1 Therapeutics, Inc. Common Stock as of Q3 2024.
Based on Barclays's 13F filing for Q3 2024, filed 15 Nov 2024.